Quantification and cell-to-cell variation of vascular endothelial growth factor receptors

Experimental Cell Research

Volumn 317, Issue 7, 2011, Pages 955-965

  Imoukhuede, P I ^a   Popel, Aleksander S ^a  

^a Johns Hopkins University   (United States)

Author keywords

Angiogenesis; Flow cytometry; NRP1; Systems biology; VEGF

Indexed keywords

NEUROPILIN 1; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ARTICLE; CELL HETEROGENEITY; CELL SURFACE; CONTROLLED STUDY; FLUORESCENCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

EID: 79952443293     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.12.014     Document Type: Article

References (70)

1. Roskoski R. VEGF receptor protein-tyrosine kinases: structure and regulation. Biochem. Biophys. Res. Commun. 2008, 375:287-291.
2. Soker S., Miao H.-Q., Nomi M., Takashima S., Klagsbrun M. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J. Cell. Biochem. 2002, 85:357-368.
3. Henry T.D., Annex B.H., McKendall G.R., Azrin M.A., Lopez J.J., Giordano F.J., Shah P.K., Willerson J.T., Benza R.L., Berman D.S., Gibson C.M., Bajamonde A., Rundle A.C., Fine J., McCluskey E.R. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003, 107:1359-1365. V.I. for the.
4. Ylä-Herttuala S., Rissanen T.T., Vajanto I., Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J. Am. Coll. Cardiol. 2007, 49:1015-1026.
5. Ferrara N., Hillan K.J., Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. 2005, 333:328-335.
6. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8:592-603.
7. Mac Gabhann F., Popel A.S. Systems biology of vascular endothelial growth factors. Microcirculation 2008, 15:715-738.
8. Stefanini M.O., Wu F.T., Mac Gabhann F., Popel A.S. A compartment model of VEGF distribution in blood, healthy and diseased tissues. BMC Syst. Biol. 2008, 2:77.
9. Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M., Heldin C.H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 1994, 269:26988-26995.
10. Seetharam L., Gotoh N., Maru Y., Neufeld G., Yamaguchi S., Shibuya M. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 1995, 10:135-147.
11. Autiero M., Waltenberger J., Communi D., Kranz A., Moons L., Lambrechts D., Kroll J., Plaisance S., De Mol M., Bono F., Kliche S., Fellbrich G., Ballmer-Hofer K., Maglione D., Mayr-Beyrle U., Dewerchin M., Dombrowski S., Stanimirovic D., Van Hummelen P., Dehio C., Hicklin D.J., Persico G., Herbert J.-M., Communi D., Shibuya M., Collen D., Conway E.M., Carmeliet P. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat. Med. 2003, 9:936-943.
12. Mac Gabhann F., Popel A.S. Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2004, 286:H153-H164.
13. Mac Gabhann F., Qutub A.A., Annex B.H., Popel A.S. Systems biology of pro-angiogenic therapies targeting the VEGF system, Wiley Interdisciplinary Reviews. Syst. Biol. Med. 2010, 2:694-707.
14. Li J., Brown L.F., Hibberd M.G., Grossman J.D., Morgan J.P., Simons M. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am. J. Physiol. Heart Circ. Physiol. 1996, 270:H1803-H1811.
15. Brown L.F., Berse B., Jackman R.W., Tognazzi K., Guidi A.J., Dvorak H.F., Senger D.R., Connolly J.L., Schnitt S.J. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol. 1995, 26:86-91.
16. Gerritsen M.E., Tomlinson J.E., Zlot C., Ziman M., Hwang S. Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells. Br. J. Pharmacol. 2003, 140:595-610.
17. Dougher M., Terman B.I. Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene 1999, 18:1619-1627.
18. Duval M., Bedard-Goulet S., Delisle C., Gratton J.-P. Vascular endothelial growth factor-dependent down-regulation of Flk-1/KDR involves cbl-mediated ubiquitination: consequences on nitric oxide production from endothelial cells. J. Biol. Chem. 2003, 278:20091-20097.
19. Vaisman N., Gospodarowicz D., Neufeld G. Characterization of the receptors for vascular endothelial growth factor. J. Biol. Chem. 1990, 265:19461-19466.
20. Prahst C., Heroult M., Lanahan A.A., Uziel N., Kessler O., Shraga-Heled N., Simons M., Neufeld G., Augustin H.G. Neuropilin-1-VEGFR-2 complexing requires the PDZ-binding domain of neuropilin-1. J. Biol. Chem. 2008, 283:25110-25114.
21. Soker S., Fidder H., Neufeld G., Klagsbrun M. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF via its exon 7-encoded domain. J. Biol. Chem. 1996, 271:5761-5767.
22. Sugiyama Y., Kawabata I., Sobue K., Okabe S. Determination of absolute protein numbers in single synapses by a GFP-based calibration technique. Nat. Meth. 2005, 2:677-684.
23. Chiu C.-S., Jensen K., Sokolova I., Wang D., Li M., Deshpande P., Davidson N., Mody I., Quick M.W., Quake S.R., Lester H.A. Number, density, and surface/cytoplasmic distribution of GABA transporters at presynaptic structures of knock-in mice carrying GABA transporter subtype 1-green fluorescent protein fusions. J. Neurosci. 2002, 22:10251-10266.
24. Schroeter P., Sablotzki A., Riemann D. CD13 and CD10 expression of granulocytes as markers for the functioning of the immune system: quantification of the expression of membrane molecules using 1:1 labeled monoclonal antibodies and flow cytometry. Meth. Mol. Biol. 2007, 378:71-81.
25. Hanley W.D., Napier S.L., Burdick M.M., Schnaar R.L., Sackstein R., Konstantopoulos K. Variant isoforms of CD44 are P- and L-selectin ligands on colon carcinoma cells. FASEB J. 2005, 05-4574fje.
26. Gampel A., Moss L., Jones M.C., Brunton V., Norman J.C., Mellor H. VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial storage compartment. Blood 2006, 108:2624-2631.
27. Scott A., Mellor H. VEGF receptor trafficking in angiogenesis. Biochem. Soc. Trans. 2009, 037:1184-1188.
28. Kobayashi S., Sawano A., Nojima Y., Shibuya M., Maru Y. The c-Cbl/CD2AP complex regulates VEGF-induced endocytosis and degradation of Flt-1 (VEGFR-1). FASEB J. 2004, 18:929-931. Epub 2004 Mar 4.
29. Aird W.C. Phenotypic heterogeneity of the endothelium: I. structure, function, and mechanisms. Circ. Res. 2007, 100:158-173.
30. Aird W.C. Phenotypic heterogeneity of the endothelium: II. representative vascular beds. Circ. Res. 2007, 100:174-190.
31. Elowitz M.B., Levine A.J., Siggia E.D., Swain P.S. Stochastic gene expression in a single cell. Science 2002, 297:1183-1186.
32. Raj A., Peskin C.S., Tranchina D., Vargas D.Y., Tyagi S. Stochastic mRNA synthesis in mammalian cells. PLoS Biol. 2006, 4:1707-1719.
33. Raj A., van Oudenaarden A. Nature, nurture, or chance: stochastic gene expression and its consequences. Cell 2008, 135:216-226.
34. Janes K.A., Wang C.-C., Holmberg K.J., Cabral K., Brugge J.S. Identifying single-cell molecular programs by stochastic profiling. Nat. Meth. 2010, 7:311-317.
35. Niepel M., Spencer S.L., Sorger P.K. Non-genetic cell-to-cell variability and the consequences for pharmacology. Curr. Opin. Chem. Biol. 2009, 13:556-561.
36. Shibuya M. Structure and dual function of vascular endothelial growth factor receptor-1. Int. J. Biochem. Cell Biol. 2001, 33:409-420.
37. Terman B.I., Dougher-Vermazen M., Carrion M.E., Dimitrov D., Armellino D.C., Gospodarowicz D., Böhlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 1992, 187:1579-1586.
38. Soker S., Takashima S., Miao H.Q., Neufeld G., Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998, 92:735-745.
39. Cao Y., Linden P., Farnebo J., Cao R., Eriksson A., Kumar V., Qi J.-H., Claesson-Welsh L., Alitalo K. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc. Natl. Acad. Sci. USA 1998, 95:14389-14394.
40. Witzenbichler B., Asahara T., Murohara T., Silver M., Spyridopoulos I., Magner M., Principe N., Kearney M., Hu J.-S., Isner J.M. Vascular endothelial growth Factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am. J. Pathol. 1998, 153:381-394.
41. Lili W., Fatima A., Adolfas K.G., Robert F.V., Gerald E.M. Comparison of fluorescein and phycoerythrin conjugates for quantifying CD20 expression on normal and leukemic B-cells. Cytom. B Clin. Cytom. 2006, 70B:410-415.
42. Kulwinder K.P., Edward T.J., Sujata B.I. Performance evaluation of quantiBRITE phycoerythrin beads. Cytometry 2001, 45:250-258.
43. Gero B., Ferdinand H., Ruth K. Flow cytometric detection and quantitation of the epidermal growth factor receptor in comparison to Scatchard analysis in human bladder carcinoma cell lines. Cytometry 1994, 17:75-83.
44. Craig L.E., Spelman J.P., Strandberg J.D., Zink M.C. Endothelial cells from diverse tissues exhibit differences in growth and morphology. Microvasc. Res. 1998, 55:65-76.
45. Lee T.-H., Seng S., Sekine M., Hinton C., Fu Y., Avraham H.K., Avraham S. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med. 2007, 4:e186.
46. Lee T.-H., Avraham H.K., Jiang S., Avraham S. Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability. J. Biol. Chem. 2003, 278:5277-5284.
47. Price D.J., Miralem T., Jiang S., Steinberg R., Avraham H. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ. 2001, 12:129-135.
48. Langenkamp E., Molema G. Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer. Cell Tissue Res. 2009, 335:205-222.
49. Swartz M.A., Skobe M. Lymphatic function, lymphangiogenesis, and cancer metastasis. Microsc. Res. Tech. 2001, 55:92-99.
50. Joukov V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., Saksela O., Kalkkinen N., Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996, 15:290-298.
51. Achen M.G., Jeltsch M., Kukk E., Mäkinen T., Vitali A., Wilks A.F., Alitalo K., Stacker S.A. Vascular endothelial growth factor D. Proc. Natl. Acad. Sci. USA 1998, 95:548-553.
52. Goldman J., Rutkowski J.M., Shields J.D., Pasquier M.C., Cui Y., Schmokel H.G., Willey S., Hicklin D.J., Pytowski B., Swartz M.A. Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis. FASEB J. 2007, 21:1003-1012.
53. Achen M.G., Stacker S.A. Molecular control of lymphatic metastasis. Ann. NY Acad. Sci. 2008, 1131:225-234.
54. Alabi A., Suppiah A., Madden L., Monson J., Greenman J. Preoperative serum levels of serum VEGF-C is associated with distant metastasis in colorectal cancer patients. Int. J. Colorectal Dis. 2009, 24:269-274.
55. Al-Moundhri M.S., Al-Shukaili A., Al-Nabhani M., Al-Bahrani B., Burney I.A., Rizivi A., Ganguly S.S. Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma. World J. Gastroenterol. 2008, 14:3879-3883.
56. Wang T.B., Deng M.H., Qiu W.S., Dong W.G. Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J. Gastroenterol. 2007, 13:1794-1797. discussion 1797-1798.
57. Chen J.-H., Wang X.-C., Kan M., Sato J.D. Effect of FGF-1 and FGF-2 on VEGF binding to human umbilical vein endothelial cells. Cell Biol. Int. 2001, 25:257-260.
58. Thien C.B.F., Langdon W.Y. Cbl: many adaptations to regulate protein tyrosine kinases. Nat. Rev. Mol. Cell Biol. 2001, 2:294-307.
59. Nilsson I., Bahram F., Li X., Gualandi L., Koch S., Jarvius M., Soderberg O., Anisimov A., Kholova I., Pytowski B., Baldwin M., Yla-Herttuala S., Alitalo K., Kreuger J., Claesson-Welsh L. VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts. EMBO J. 2010, 29:1377-1388.
60. Neagoe P.E., Lemieux C., Sirois M.G. Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer. J. Biol. Chem. 2005, 280:9904-9912.
61. Huang K., Andersson C., Roomans G.M., Ito N., Claesson-Welsh L. Signaling properties of VEGF receptor-1 and -2 homo- and heterodimers. Int. J. Biochem. Cell Biol. 2001, 33:315-324.
62. Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci. Signal. 2009, 2. re1-.
63. Geretti E., Klagsbrun M. Neuropilins: novel targets for anti-angiogenesis therapies. Cell Adh Migr. 2007, 1:56-61.
64. Jarvis A., Allerston C.K., Jia H., Herzog B., Garza-Garcia A., Winfield N., Ellard K., Aqil R., Lynch R., Chapman C., Hartzoulakis B., Nally J., Stewart M., Cheng L., Menon M., Tickner M., Djordjevic S., Driscoll P.C., Zachary I., Selwood D.L. Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. J. Med. Chem. 2010, 53:2215-2226.
65. Nasarre C., Roth M., Jacob L., Roth L., Koncina E., Thien A., Labourdette G., Poulet P., Hubert P., Cremel G., Roussel G., Aunis D., Bagnard D. Peptide-based interference of the transmembrane domain of neuropilin-1 inhibits glioma growth in vivo. Oncogene 2010, 29:2381-2392.
66. Pan Q., Chanthery Y., Liang W.-C., Stawicki S., Mak J., Rathore N., Tong R.K., Kowalski J., Yee S.F., Pacheco G., Ross S., Cheng Z., Le Couter J., Plowman G., Peale F., Koch A.W., Wu Y., Bagri A., Tessier-Lavigne M., Watts R.J. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007, 11:53-67.
67. Zhang Z., Neiva K., Lingen M., Ellis L., Nor J. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ. 2010, 499-512.
68. Murdaca J., Treins C., Monthouel-Kartmann M.-N., Pontier-Bres R., Kumar S., Van Obberghen E., Giorgetti-Peraldi S. Grb10 prevents Nedd4-mediated vascular endothelial growth factor receptor-2 degradation. J. Biol. Chem. 2004, 279:26754-26761.
69. Lampugnani M.G., Orsenigo F., Gagliani M.C., Tacchetti C., Dejana E. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J. Cell Biol. 2006, 174:593-604.
70. Bhattacharya R., Kang-Decker N., Hughes D.A., Mukherjee P., Shah V., McNiven M.A., Mukhopadhyay D. Regulatory role of dynamin-2 in VEGFR-2/KDR-mediated endothelial signaling. FASEB J. 2005, 1692-1694.